Avenzo Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation small-molecule and antibody-drug conjugate (ADC) therapies for oncology. Founded in 2022 by veterans of Turning Point Therapeutics (acquired by Bristol Myers Squibb for $4.1B in 2022), the San Diego-based company targets cancers with high unmet medical needs. The company has raised over $60M in Series B financing with backing from OrbiMed, Foresite Capital, SR One, NEA, Lilly Asia Ventures, Sands Capital, and others.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountSep 2025
Nov 2024
Mar 2024
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
